Epirubicin

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
US
  • Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer
Product first approved 1999Outside this platform's coverageFDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (95)
Breast Cancer
NCT07441460 · Shanghai JMT-Bio Inc.
2026-03-06 – 2035-08-07 · Resectable HER2-positive Breast Cancer
What this study did
NCT06966700 · Merck Sharp & Dohme LLC
2025-06-30 – 2034-12-29 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
What this study did
NCT02455141 · Shanghai Jiao Tong University School of Medicine
2016-03 – 2030-03 · Breast Neoplasm
What this study did
NCT00433420 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2003-04 – 2027-12 · Breast Cancer
What this study did
NCT00301925 · Institute of Cancer Research, United Kingdom
2005-12-16 – 2024-09 · Breast Cancer
What this study did
NCT03013504 · Prestige Biopharma Limited
2018-02-19 – 2022-01-13 · HER2 Positive Breast Cancer
What this study did
NCT03556358 · Tanvex BioPharma USA, Inc.
2018-06-28 – 2021-02-04 · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
What this study did
NCT00630032 · UNICANCER
2007-09 – 2020-09-03 · Breast Cancer
What this study did
NCT01690702 · GBG Forschungs GmbH
2012-09 – 2020-07-20 · Breast Cancer
What this study did
NCT01134523 · Chinese Academy of Medical Sciences
2010-05 – 2020-05 · Breast Cancer
What this study did
NCT00129935 · Spanish Breast Cancer Research Group
2004-02 – 2019-04-04 · Breast Cancer
What this study did
NCT01222052 · Martin-Luther-Universität Halle-Wittenberg
2002-01 – 2019-02 · Breast Cancer
What this study did
NCT01314833 · Fudan University
2010-06-01 – 2017-06-15 · Primary Breast Cancer
What this study did
NCT02980965 · Fudan University
2013-05 – 2017-02 · Breast Cancer Female
What this study did
NCT01026116 · Fudan University
2009-12 – 2016-12-23 · Breast Neoplasms
What this study did
NCT00087178 · NSABP Foundation Inc
2004-05 – 2016-05 · Breast Cancer
What this study did
NCT00567554 · GBG Forschungs GmbH
2007-10 – 2015-10 · Breast Cancer
What this study did
NCT01479036 · Xijing Hospital
2011-10 – 2015-02 · Breast Cancer
What this study did
NCT02324088 · UNICANCER
2000-10 – 2015-01 · Inflammatory Breast Cancer
What this study did
NCT00625898 · NSABP Foundation Inc
2008-04 – 2014-07 · Breast Cancer
What this study did
NCT03888677 · Henrik Lindman
2001-02 – 2014-07 · Breast Cancer
What this study did
NCT00014222 · NCIC Clinical Trials Group
2000-12-04 – 2014-03-17 · Breast Cancer
What this study did
NCT00010140 · International Collaborative Cancer Group
started 1997-08 · Breast Cancer
What this study did
NCT00005581 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
started 2000-06 · Breast Cancer
What this study did
NCT01433614 · Thomas Hatschek
2002-12 – 2013-12 · Metastatic Breast Cancer
What this study did
NCT00003012 · Scottish Cancer Therapy Network
started 1996-10 · Breast Cancer
What this study did
NCT00516425 · Charing Cross Hospital
started 2007-01 · Breast Cancer
What this study did
NCT00039546 · Cancer Research Campaign Clinical Trials Centre
started 2001-08 · Breast Cancer
What this study did
NCT00424606 · Hellenic Oncology Research Group
2001-06 – 2013-08 · Breast Cancer
What this study did
NCT00055679 · UNICANCER
2002-08 – 2013-06 · Breast Cancer
What this study did
NCT00513292 · National Cancer Institute (NCI)
2007-07 – 2013-02-21 · HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
What this study did
NCT00615602 · Hellenic Oncology Research Group
2004-10 – 2012-05 · Breast Cancer
What this study did
NCT02450058 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
1996-11 – 2012-05 · Breast Cancer, Chemotherapy, Adjuvant
What this study did
NCT01093235 · Cambridge University Hospitals NHS Foundation Trust
2009-04 – 2012-04 · Breast Cancer, Cardiac Toxicity, Perioperative/Postoperative Complications
What this study did
NCT00047099 · Ludwig-Maximilians - University of Munich
2001-08 – 2012-03 · Breast Cancer
What this study did
NCT00309556 · Austrian Breast & Colorectal Cancer Study Group
2005-02 – 2011-11 · Breast Cancer
What this study did
NCT00038402 · M.D. Anderson Cancer Center
2001-04 – 2011-07 · Breast Cancer
What this study did
NCT00963729 · Imperial College London
2008-09 – 2011-03 · Breast Cancer
What this study did
NCT00002542 · NCIC Clinical Trials Group
1993-07-20 – 2011-01-11 · Breast Cancer
What this study did
NCT01031030 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
1997-11 – 2010-12 · Breast Cancer
What this study did
NCT00629278 · Azienda Ospedaliero-Universitaria di Modena
2007-12 – 2010-12 · Breast Cancer
What this study did
NCT00336791 · M.D. Anderson Cancer Center
2003-09 – 2010-09 · Breast Cancer
What this study did
NCT00002529 · ETOP IBCSG Partners Foundation
1993-05 – 2010-08 · Breast Cancer
What this study did
Phase 2/3 (12)
Breast Cancer
NCT02641847 · Fudan University
2016-01 – 2027-12 · Triple Negative Breast Cancer, Breast Cancer
What this study did
NCT04576143 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-09-20 – 2027-09-20 · HER2-negative Breast Cancer, Neoadjuvant Chemotherapy
What this study did
NCT04290793 · Hebei Medical University Fourth Hospital
2020-03-01 – 2026-12-10 · Breast Cancer
What this study did
NCT01779206 · Women's Cancer Study Group GmbH
2012-05 – 2025-01-15 · Breast Cancer
What this study did
NCT01907529 · Hebei Medical University Fourth Hospital
2019-08 – 2021-12 · Stage III Breast Cancer
What this study did
NCT03373708 · Zhiyong Yu
2017-12-20 – 2019-12-20 · Breast Cancer, Chemotherapy, Endocrine Breast Diseases
What this study did
NCT03349177 · Zhiyong Yu
2017-11-27 – 2019-11-27 · Breast Cancer, Pathological Complete Response, Neoadjuvant Chemotherapy
What this study did
NCT01150513 · Chinese Academy of Medical Sciences
2009-06 – 2016-04 · Breast Cancer
What this study did
Other / comorbidity
NCT02871869 · Xinjiang Medical University
2016-09 – 2021-12 · Diffuse, Large B-Cell, Lymphoma
What this study did
NCT00450203 · Professor David Cunningham
2007-10 – 2017-12 · Oesophagogastric Cancer
What this study did
NCT00843934 · Nihon University
2009-03 – 2015-02 · Carcinoma, Hepatocellular
What this study did
NCT00960284 · IRCCS San Raffaele
2003-06 – 2009-06 · Pancreatic Cancer
What this study did
Phase 2 (157)
Breast Cancer
NCT02315196 · Rutgers, The State University of New Jersey
2015-02-25 – 2041-07 · Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
What this study did
NCT07016399 · Vandana Abramson
2025-09-09 – 2033-10 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
What this study did
NCT06291064 · University of Chicago
2025-03-18 – 2032-06 · Triple Negative Breast Cancer
What this study did
NCT05900206 · Karolinska University Hospital
2023-10-26 – 2032-04-30 · Breast Cancer
What this study did
NCT06829199 · Merck Sharp & Dohme LLC
2025-03-26 – 2031-03-18 · Early Triple Negative Breast Cancer
What this study did
NCT06964906 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-03-04 – 2030-12-31 · ER+/HER2- Breast Cancer
What this study did
NCT06404463 · Fudan University
2024-05-06 – 2030-11-06 · Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer
What this study did
NCT04771871 · University College Hospital, Ibadan
2021-11-29 – 2030-08 · Triple Negative Breast Cancer
What this study did
NCT02624973 · Haukeland University Hospital
2016-04-15 – 2030-06 · Breast Cancer
What this study did
NCT06860529 · Henan Cancer Hospital
2025-04-15 – 2030-03-31 · HR+/HER2- Breast Cancer
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07900516 · The First Affiliated Hospital with Nanjing Medical University
2026-08-01 – 2028-08-01 · Breast Cancer
What this study did
NCT05165225 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-07-13 – 2028-03-31 · Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer, Neoadjuvant Therapy
What this study did
NCT05978648 · wang shusen
2023-09-20 – 2027-12-31 · Breast Neoplasms
What this study did
NCT04437160 · Chinese Academy of Medical Sciences
2020-02-01 – 2027-12 · Triple Negative Breast Cancer
What this study did
NCT05983094 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-09-01 – 2027-09-01 · Breast Cancer, Neoadjuvant Therapy
What this study did
NCT05447702 · West China Hospital
2022-11-01 – 2026-12-31 · Triple Negative Breast Cancer
What this study did
NCT06470633 · The First Affiliated Hospital with Nanjing Medical University
2024-08-01 – 2026-12-31 · Breast Cancer, HR+/HER2- Breast Cancer
What this study did
NCT06500208 · Shanghai Jiao Tong University School of Medicine
2024-11-01 – 2026-12-31 · Breast Cancer
What this study did
NCT06227117 · RemeGen Co., Ltd.
2023-07-27 – 2026-12 · Breast Cancer
What this study did
NCT05834582 · The First Affiliated Hospital with Nanjing Medical University
2023-04-08 – 2026-06-01 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT00496795 · University of Bergen
2007-09 – 2026-05 · Stage III Breast Cancer AJCC V7
What this study did
NCT04877821 · Guangdong Provincial People's Hospital
2021-09-15 – 2026-03-10 · Triple Negative Breast Cancer
What this study did
NCT04418154 · Fudan University
2020-06-09 – 2025-12-31 · Triple Negative Breast Cancer
What this study did
NCT01740271 · AHS Cancer Control Alberta
2012-12 – 2025-06 · Breast Neoplasms
What this study did
NCT05491694 · The First Affiliated Hospital with Nanjing Medical University
2022-09-01 – 2024-12-30 · Breast Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT04770272 · Palleos Healthcare GmbH
2021-03-01 – 2024-10-02 · Triple-negative Breast Cancer
What this study did
NCT02897050 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2016-09 – 2024-09 · Breast Cancer
What this study did
NCT05681728 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2022-02-01 – 2024-06-01 · Breast Cancer
What this study did
NCT04717531 · The First Affiliated Hospital with Nanjing Medical University
2021-06-03 – 2024-05-31 · Breast Cancer
What this study did
NCT04676997 · Shandong Cancer Hospital and Institute
2020-05-20 – 2024-02-28 · Triple Negative Breast Cancer
What this study did
NCT04498793 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2020-09 – 2022-12 · HER2-negative Breast Cancer
What this study did
NCT01036087 · M.D. Anderson Cancer Center
2010-11 – 2022-08-09 · Breast Cancer
What this study did
NCT01779050 · Washington University School of Medicine
2013-12-19 – 2021-09-01 · Breast Neoplasms
What this study did
NCT03894007 · Renske Altena
2019-05-23 – 2021-06-30 · Early-stage Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT02682693 · GBG Forschungs GmbH
2017-02-13 – 2020-12-31 · Breast Cancer Female NOS, Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer, Tubular Breast Cancer Stage III
What this study did
NCT01593020 · M.D. Anderson Cancer Center
2012-08-03 – 2020-11-04 · Breast Cancer
What this study did
NCT01929811 · Shanghai Jiao Tong University School of Medicine
2013-10 – 2020-06 · pCR Rate, BCT Rate, Safety
What this study did
NCT04659551 · Istituto Oncologico Veneto IRCCS
2017-10-05 – 2020-05-25 · Breast Cancer
What this study did
NCT02789332 · GBG Forschungs GmbH
2016-09 – 2020-02 · Breast Cancer, Triple Negative Breast Neoplasms, HRpos Breast Neoplasms, BRCA 1 /2 and / or HRD
What this study did
NCT03154749 · Guangdong Provincial People's Hospital
2016-09-01 – 2019-12-31 · Triple-Negative Breast Cancer
What this study did
NCT00820547 · UNICANCER
2009-01 – 2019-09 · Breast Cancer
What this study did
NCT02628613 · Fudan University
2015-12 – 2019-02 · Breast Cancer
What this study did
NCT02909751 · Vejle Hospital
2016-09-14 – 2019-01-21 · Breast Cancer
What this study did
NCT02694224 · Clinica Universidad de Navarra, Universidad de Navarra
2016-04 – 2018-12 · Breast Cancer
What this study did
NCT01855828 · Yale University
2013-09 – 2018-08 · Her2-Positive Breast Cancer
What this study did
Phase 1/2 (17)
Breast Cancer
NCT05981014 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-08-01 – 2035-05-31 · Breast Neoplasms
What this study did
NCT07739485 · Liu Shu
2026-07-30 – 2029-07-30 · Triple -Negative Breast Cancer
What this study did
NCT03356860 · Grand Hôpital de Charleroi
2017-04-13 – 2023-12-31 · Breast Cancer, Triple Negative Breast Cancer, Luminal B
What this study did
NCT04213898 · Henan Cancer Hospital
2020-01 – 2023-01 · Triple-negative Breast Cancer
What this study did
NCT01936064 · Lagos State University
2016-10 – 2018-01 · Haematological Abnormality
What this study did
NCT00066443 · NCIC Clinical Trials Group
2003-11-03 – 2014-01-16 · Breast Cancer
What this study did
NCT00705315 · Hellenic Oncology Research Group
2008-05 – 2010-06 · Breast Cancer
What this study did
NCT00097383 · Eli Lilly and Company
— · Breast Cancer
What this study did
Other / comorbidity
NCT03277924 · Grupo Espanol de Investigacion en Sarcomas
2017-05-31 – 2024-06-30 · Soft Tissue Sarcoma, Bone Sarcoma
What this study did
NCT02987244 · Peking Union Medical College Hospital
2016-03 – 2023-03 · T Cell Non-Hodgkin's Lymphoma
What this study did
NCT02638857 · Second Military Medical University
2015-09 – 2017-09 · Recurrence Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
What this study did
NCT00667420 · Massachusetts General Hospital
2008-04 – 2014-06 · Esophageal Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT00719550 · Amgen
2009-02 – 2013-06 · Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer
What this study did
NCT00954512 · Merck Sharp & Dohme LLC
2009-09-25 – 2011-06-07 · Neoplasms
What this study did
NCT00057980 · Northwestern University
2002-10 – 2007-02 · Liver Cancer
What this study did
NCT00021047 · National Institutes of Health Clinical Center (CC)
2001-07 – 2004-06 · Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
Phase 1 (22)
Breast Cancer
NCT06121570 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-11-01 – 2031-08-31 · Breast Neoplasms
What this study did
NCT01880385 · Association Tunisienne de lutte Contre le Cancer
2011-03 – 2017-04 · Inflammatory Breast Cancer
What this study did
NCT01624441 · National Cancer Institute (NCI)
2012-08-21 – 2013-09-10 · Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
What this study did
NCT00753207 · Cancer Trials Ireland
2007-10 – 2012-03 · Breast Cancer
What this study did
NCT00872625 · Centre Antoine Lacassagne
2007-04 – 2010-12 · Breast Cancer
What this study did
NCT00002866 · NCIC Clinical Trials Group
1996-08-12 – 2009-12-21 · Breast Cancer, Neutropenia
What this study did
NCT00322374 · R-Pharm
2006-08 – 2009-02 · Metastatic Breast Cancer
What this study did
NCT00364754 · YM BioSciences
2004-05 – 2006-01 · Metastatic/Recurrent Breast Cancer
What this study did
NCT00008034 · European Organisation for Research and Treatment of Cancer - EORTC
2000-02 – 2000-12 · Breast Cancer
What this study did
Other / comorbidity
NCT06699576 · Hansoh BioMedical R&D Company
2024-12-20 – 2028-12-30 · Osteosarcoma, Soft Tissue Sarcoma (STS)
What this study did
NCT01386346 · Weill Medical College of Cornell University
2011-06 – 2018-09 · Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
What this study did
NCT00878904 · University of California, San Francisco
2009-09-13 – 2016-10-10 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT02867397 · Disphar International B.V.
2012-01 – 2015-08 · Patients With Advanced or Metastatic Solid Tumors
What this study did
NCT00215514 · Dana-Farber Cancer Institute
2000-09 – 2014-07 · Stomach Cancer, Gastric Cancer, Gastro-esophageal Junction Cancer
What this study did
NCT00722293 · GlaxoSmithKline
2008-07-08 – 2014-02-25 · Neoplasms, Breast
What this study did
NCT00822848 · OHSU Knight Cancer Institute
2009-02 – 2013-04-30 · Sarcoma
What this study did
NCT00486356 · University of Nebraska
2004-10-01 – 2010-01-01 · Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00246103 · H. Lee Moffitt Cancer Center and Research Institute
2004-03 – 2008-04 · Neoplasms, Advanced
What this study did
NCT00096304 · Medical University of South Carolina
2004-06-08 – 2007-11-30 · Prostate Cancer
What this study did
NCT00113581 · Merck KGaA, Darmstadt, Germany
2002-10 – 2007-01 · Esophageal Cancer, Gastric Cancer
What this study did
NCT00020748 · Georgetown University
2000-08 – 2004-10 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
Phase 4 (10)
Breast Cancer
NCT05420454 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-10 – 2027-12-20 · Breast Cancer
What this study did
NCT05420467 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-10 – 2027-12-20 · Breast Cancer
What this study did
NCT04137640 · Shengjing Hospital
2021-07-19 – 2026-05-31 · Breast Cancer
What this study did
NCT02627248 · Shandong University
2015-10 – 2025-10 · Breast Cancer
What this study did
NCT02549677 · Ruijin Hospital
2015-10 – 2020-03 · Breast Neoplasms
What this study did
NCT03799679 · Fudan University
2018-11-26 – 2020-02-01 · Triple Negative Breast Cancer
What this study did
NCT01199432 · Tao OUYANG
2010-10 – 2014-12 · Breast Cancer
What this study did
Other / comorbidity
NCT02752815 · Ruijin Hospital
2016-06-14 – 2024-12-31 · Diffuse Large B-cell Lymphoma
What this study did
NCT02631499 · Fudan University
2015-12 – 2019-12 · Carcinoma, Hepatocellular, Neoplastic Cells, Circulating
What this study did
NCT02214602 · Mansoura University
2014-07 – 2017-05 · Carcinoma of Urinary Bladder, Superficial
What this study did
Early phase / not applicable (17)
Breast Cancer
NCT05287308 · Chinese Academy of Medical Sciences
2022-03 – 2027-09 · Breast Cancer
What this study did
NCT06975644 · Zhejiang Provincial People's Hospital
2025-09-01 – 2026-12-31 · Triple-Negative Breast Cancer (TNBC), Neoadjuvant Chemotherapy, Chemotherapy Effects
What this study did
NCT04067102 · Hebei Medical University Fourth Hospital
2019-05-10 – 2026-05 · Triple Negative Breast Cancer
What this study did
NCT05296317 · Centre Georges Francois Leclerc
2022-09-02 – 2025-09-26 · Localized Breast Cancer
What this study did
NCT05914753 · Zhejiang Provincial People's Hospital
2023-07-01 – 2025-06-01 · Breast Cancer, Chemotherapy Effect
What this study did
NCT01503905 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2011-12 – 2021-12 · Breast Cancer Nos Premenopausal
What this study did
NCT03647280 · Zhejiang Cancer Hospital
2018-12-01 – 2020-09-30 · Breast Cancer
What this study did
NCT01159236 · M.D. Anderson Cancer Center
started 2010-09 · Breast Cancer
What this study did
NCT00309920 · Heinrich-Heine University, Duesseldorf
started 2004-01 · Breast Cancer
What this study did
NCT00617370 · Memorial Sloan Kettering Cancer Center
2004-11 – 2008-06 · Breast Cancer, Adenocarcinoma of the Breast
What this study did
NCT00146588 · Craig A. Bunnell, MD, MPH
2002-04 – 2004-12 · Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
What this study did
Other / comorbidity
NCT05084586 · Ankara Training and Research Hospital
2019-10-01 – 2023-11-05 · Bladder Cancer, Epirubicin Adverse Reaction, Superficial Bladder Cancer, Tumor Recurrence
What this study did
NCT05204524 · Chinese Academy of Medical Sciences
2021-08-27 – 2023-08-27 · Leiomyosarcoma
What this study did
NCT05146635 · Mansoura University
2021-12-01 – 2023-01-01 · Bladder Cancer
What this study did
NCT03113955 · Varian Medical Systems
2017-10-24 – 2020-02-28 · Localized Hepatocellular Carcinoma
What this study did
NCT03022123 · Hebei Medical University Fourth Hospital
2016-11 – 2018-03 · Diffuse Large B-cell Lymphoma
What this study did
Used as active comparator (51)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (25)
Breast Cancer
NCT05901428 · Fudan University
2023-06-01 – 2032-06 · Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
NCT05883852 · Fudan University
2023-06-07 – 2031-07-01 · HER2 Positive Early Breast Cancer
What this study did
NCT06795503 · Fudan University
2025-02 – 2031-07 · Triple-negative Breast Cancer
What this study did
NCT04193059 · Fudan University
2019-12-20 – 2027-07 · Breast Cancer
What this study did
NCT04296175 · Fudan University
2020-03-05 – 2027-03 · Triple-negative Breast Cancer
What this study did
NCT02535221 · Peking University
2015-07-29 – 2026-12-31 · Breast Cancer
What this study did
NCT03876886 · Chinese Academy of Medical Sciences
2019-02-22 – 2024-12 · Triple Negative Breast Cancer
What this study did
NCT02879513 · RenJi Hospital
2014-01 – 2022-12 · Invasive Ductal Breast Cancer, Tubular Breast Cancer, Mucinous Breast Cancer, Inflammatory Breast Cancer
What this study did
NCT01642771 · China Breast Cancer Clinical Study Group
2012-06 – 2020-05 · Breast Cancer
What this study did
NCT01049425 · Women's Cancer Study Group GmbH
2009-02-05 – 2018-05-15 · Primary Breast Cancer, Her2 Non-overexpressing
What this study did
NCT00776724 · National Taiwan University Hospital
2008-05-29 – 2017-04-19 · Breast Cancer, Chemotherapy
What this study did
NCT02125344 · GBG Forschungs GmbH
2014-12 – 2017-01-30 · Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer
What this study did
NCT01216111 · Fudan University
2011-01-01 – 2016-04-20 · Triple Negative Breast Cancer
What this study did
NCT01985724 · Hellenic Oncology Research Group
2007-10 – 2013-12 · Breast Cancer
What this study did
NCT00689156 · Danish Breast Cancer Cooperative Group
2008-06 – 2013-01 · Breast Neoplasms
What this study did
Other / comorbidity
NCT07424287 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-07-13 – 2030-06 · NMIBC
What this study did
NCT04736394 · Jiangsu Yahong Meditech Co., Ltd aka Asieris
2021-09-29 – 2025-12-31 · Non-muscle Invasive Bladder Cancer
What this study did
NCT00407186 · Dutch Colorectal Cancer Group
2007-01-11 – 2025-12 · Gastric Cancer
What this study did
NCT05472896 · Gao-jun Teng
2022-06-09 – 2024-06-30 · Hepatocellular Carcinoma
What this study did
NCT01710176 · Italian Sarcoma Group
2011-06-01 – 2024-06-30 · Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
What this study did
NCT02395640 · Fudan University
2015-03 – 2021-02-23 · Gastric Cancer
What this study did
NCT02767674 · The First Affiliated Hospital with Nanjing Medical University
2016-05 – 2020-12 · Diffuse Large B Cell Lymphoma
What this study did
NCT02755311 · Sun Yat-sen University
2014-03 – 2016-06 · Hepatocellular Carcinoma
What this study did
Phase 2/3 (5)
Breast Cancer
NCT06009627 · Tianjin Medical University Cancer Institute and Hospital
2023-04-11 – 2025-09-11 · Breast Cancer
What this study did
NCT05253066 · Shengjing Hospital
2022-02-25 – 2025-01-31 · Breast Neoplasms
What this study did
NCT01204437 · GBG Forschungs GmbH
2009-03 – 2014-01 · Breast Cancer
What this study did
Other / comorbidity
NCT01404156 · Dr. Gordon Buduhan
2015-09 – 2023-08 · Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
What this study did
Phase 2 (12)
Breast Cancer
NCT06107673 · Hebei Medical University Fourth Hospital
2023-09-30 – 2028-12-01 · Breast Cancer
What this study did
NCT04138719 · Hebei Medical University Fourth Hospital
2019-11-20 – 2028-06-20 · Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel
What this study did
NCT04172259 · Sun Yat-sen University
2019-01-10 – 2026-09-30 · Breast Cancer, Neoadjuvant Chemotherapy
What this study did
NCT03609047 · European Organisation for Research and Treatment of Cancer - EORTC
2019-06-14 – 2026-09-30 · Breast Cancer Stage II, Breast Cancer Stage III
What this study did
NCT01210768 · TTY Biopharm
2010-06 – 2022-10-31 · Breast Cancer
What this study did
NCT02742051 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2016-06 – 2020-03-14 · Breast Cancer
What this study did
NCT02685059 · GBG Forschungs GmbH
2016-06 – 2018-03 · Breast Cancer
What this study did
NCT02041338 · Chinese Academy of Medical Sciences
2014-01 – 2017-12 · Breast Cancer, Neoadjuvant Chemotherapy
What this study did
NCT02510781 · Hospital Affiliated to Military Medical Science, Beijing
2015-01 – 2017-12 · Breast Neoplasms
What this study did
NCT01276769 · Chinese Academy of Medical Sciences
2008-01 – 2012-07 · Triple Negative Breast Cancer
What this study did
Other / comorbidity
Phase 1/2 (1)
Other / comorbidity
NCT06421948 · Yanyan Liu
2024-05-25 – 2027-12-31 · Peripheral T-cell Lymphoma
What this study did
Phase 4 (5)
Breast Cancer
NCT04136782 · Shengjing Hospital
2021-07-19 – 2026-11-30 · Breast Cancer
What this study did
NCT03123770 · Zhejiang University
2016-12 – 2021-12 · Breast Cancer
What this study did
NCT02207361 · Tianjin Medical University Cancer Institute and Hospital
2013-12 – 2016-12 · Metastatic Breast Cancer
What this study did
NCT00531973 · Catholic University, Italy
2007-01 – 2009-12 · Breast Cancer
What this study did
Other / comorbidity
NCT03892330 · Shengjing Hospital
2019-06-01 – 2045-06-30 · 0.5-14 Year Old Children With Nephroblastoma
What this study did
Early phase / not applicable (3)
Breast Cancer
Other / comorbidity
NCT05053386 · Zhejiang Cancer Hospital
2021-10 – 2023-04 · Hepatocellular Carcinoma
What this study did
NCT02760953 · Huashan Hospital
2017-10-19 – 2018-12-31 · Urinary Bladder Neoplasms
What this study did
Appears in other studies (26)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (13)
Breast Cancer
NCT04335669 · Lund University Hospital
2019-12-20 – 2035-09 · Breast Cancer, Triple Negative Breast Neoplasms
What this study did
NCT06144944 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-01-17 – 2031-01-31 · Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
What this study did
NCT05474690 · Henan Cancer Hospital
2022-05-11 – 2024-08-30 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT00912444 · Shanghai Jiao Tong University School of Medicine
2009-07 – 2015-10 · Breast Cancer
What this study did
NCT01378533 · Chinese Academy of Medical Sciences
2011-05 – 2013-06 · Breast Cancer
What this study did
Other / comorbidity
NCT02971345 · Shanghai Zhongshan Hospital
2017-01 – 2020-11 · Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
What this study did
NCT02630108 · Shanghai Zhongshan Hospital
2015-12 – 2018-04 · Carcinoma, Hepatocellular
What this study did
NCT01053390 · Shanghai Jiao Tong University School of Medicine
2009-10 – 2013-12 · Gallbladder Neoplasms
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT01924819 · Australasian Gastro-Intestinal Trials Group
2009-09 – 2026-12-31 · Gastric Cancer
What this study did
NCT00525642 · Fudan University
2003-06 – 2015-06 · Breast Neoplasms, Adjuvant, Chemotherapy
What this study did
Phase 2 (7)
Breast Cancer
NCT04872985 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-04-20 – 2028-12-31 · Breast Cancer, Hormone-receptor Positive Breast Cancer
What this study did
NCT05483439 · Shengjing Hospital
2021-10-20 – 2023-07-01 · Stage II-III Breast Cancer
What this study did
NCT03273595 · Xijing Hospital
2016-07 – 2019-12 · Neoplasms, Breast
What this study did
NCT03140553 · Guangdong Provincial People's Hospital
2016-09-01 – 2019-11-11 · HER2-Positive Breast Cancer
What this study did
NCT01641406 · Auxilio Mutuo Cancer Center
2011-03 – 2013-03 · Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma
What this study did
Other / comorbidity
NCT00737438 · Memorial Sloan Kettering Cancer Center
2008-08 – 2015-02 · Esophageal Cancer, Gastric Cancer
What this study did
NCT01123473 · European Organisation for Research and Treatment of Cancer - EORTC
2010-12 – 2014-09 · Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer
What this study did
Phase 1 (1)
Breast Cancer
NCT02897700 · Shanghai Jiao Tong University School of Medicine
2013-01 – 2027-12 · Breast Cancer
What this study did
Phase 4 (1)
Early phase / not applicable (2)
Breast Cancer
NCT03756090 · Zhejiang Cancer Hospital
2018-12-01 – 2020-11-30 · Breast Cancer, Breast Diseases, Breast Neoplasms
What this study did
Other / comorbidity
NCT04738188 · Beijing Tsinghua Chang Gung Hospital
2020-03-18 – 2025-12 · Hepatocellular Carcinoma
What this study did

Competitive landscape

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Epirubicin: this drugApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(30 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Epirubicin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Phase 2/3Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04290793 · CT.gov ↗
What to watch
Phase 1Osteosarcoma, Soft Tissue Sarcoma (STS)Not yet recruiting
Est. primary completion 2026-12-30 · NCT06699576 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT05978648 · CT.gov ↗
What to watch
Phase 2Bladder Cancer, Non-muscle InvasiveActive not recruiting
Est. primary completion 2026-12-31 · NCT05024734 · CT.gov ↗
What to watch
2027 (12)
March 2027 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-03 · NCT04771871 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-03 · NCT02455141 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05900206 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4Breast CancerRecruiting
Est. primary completion 2027-06-10 · NCT05420454 · CT.gov ↗
What to watch
July 2027 (2)
Phase 4Breast CancerRecruiting
Est. primary completion 2027-07-10 · NCT05420467 · CT.gov ↗
What to watch
Phase 1/2Breast CancerRecruiting
Est. primary completion 2027-07-30 · NCT07739485 · CT.gov ↗
What to watch
September 2027 (1)
Early phase / not applicableBreast CancerNot yet recruiting
Est. primary completion 2027-09 · NCT05287308 · CT.gov ↗
What to watch
December 2027 (5)
Phase 3Peripheral T-cell Lymphoma Targeted TherapyEnrolling by invitation
Est. primary completion 2027-12-01 · NCT05678933 · CT.gov ↗
What to watch
Phase 2Adenoid Cystic Carcinoma, Sinonasal Carcinoma, EpirubicinRecruiting
Est. primary completion 2027-12-12 · NCT07320508 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT06964906 · CT.gov ↗
What to watch
2028 (8)
March 2028 (2)
Phase 2Down Syndrome, Acute Lymphoblastic Leukemia, Childhood CancerActive not recruiting
Est. primary completion 2028-03-31 · NCT03286634 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-03-31 · NCT06860529 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Adenoid Cystic CarcinomaRecruiting
Est. primary completion 2028-06-01 · NCT07616141 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-08-01 · NCT07900516 · CT.gov ↗
What to watch
Phase 2Nodal T-follicular Helper Cell LymphomaNot yet recruiting
Est. primary completion 2028-08-31 · NCT07753642 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-09-01 · NCT07016399 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Adenoid Cystic Carcinoma, Sinonasal CarcinomaRecruiting
Est. primary completion 2028-10-01 · NCT07522879 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2028-11-20 · NCT06112379 · CT.gov ↗
What to watch
2029 (2)
June 2029 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2029-06 · NCT06291064 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2029-12-31 · NCT06797635 · CT.gov ↗
What to watch
2030 (2)
November 2030 (1)
Phase 2Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low GradeNot yet recruiting
Est. primary completion 2030-11-30 · NCT06227065 · CT.gov ↗
What to watch
December 2030 (1)
Phase 1/2Breast CancerRecruiting
Est. primary completion 2030-12-31 · NCT05981014 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
2034 (1)
August 2034 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2034-08-07 · NCT07441460 · CT.gov ↗
What to watch

See the full readout calendar ↗